Company news
Clever Culture Systems Limited (ASX:CC5) news
Clever Culture Systems Limited news releases on 6ix. Latest, Sep 7, 2026: Novo Nordisk Expand Use of APAS Independence
Press releases & updates
Novo Nordisk Expand Use of APAS Independence
September 6, 2026
Half Yearly Report and Accounts
February 16, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 27, 2026
Appendix 4E
August 28, 2025
APAS Contact Plate Application Product Launch
August 26, 2025
Instrument Sale to Novo Nordisk for Group Evaluation
July 13, 2025
Additional Four Instruments Ordered by AstraZeneca
December 4, 2024
LBT Announce Bristol Myers Squibb Purchase APAS Independence
October 21, 2024
ASTRAZENECA SALE & SERVICE CONTRACT UP TO A$4.1M
August 6, 2024
Response to ASX Price Query
June 13, 2024
Lift of Pause in Trading
June 13, 2024
Pause in Trading
June 13, 2024
APAS PHARMAQC SALE TO NOVACINA
April 28, 2024
APAS PharmaQC Commercially Ready - Performance Finalised
March 12, 2024
Delivery Completes First Sale of APAS PharmaQC
February 21, 2024
Placement Completes Financial Restructure
November 19, 2023
Renounceable Rights Issue Results
November 15, 2023
$1.7M SA Government Loan Restructure
November 5, 2023
Entitlement Offer Underwriting Increased to $3.6M
October 26, 2023
Prospectus
October 12, 2023
$4.5 million Entitlement Offer
October 12, 2023
Full Repayment of $1.38M Share Placement Facility
October 12, 2023
Preliminary Annual Financial Report & Appendix 4E
August 30, 2023
Non-Cash Impairment of Intangible Assets
August 3, 2023
Placement Supports APAS Pharma & EU Expansion
March 19, 2023
AstraZeneca Partners LBT for APAS Pharma Development
January 8, 2023
LBT Strengthens APAS Pharma Development
December 19, 2022
CCS Appoint Thermo Fisher as Exclusive European Distributor
December 18, 2022
Non-renounceable Rights Issue Results
November 28, 2022
Rights Issue Prospectus
October 24, 2022
Non-Renounceable Rights Issue
October 24, 2022
$1.5M Funding Awarded for New APAS Instrument
October 23, 2022
Direct Sale of APAS Independence in United States
May 3, 2022
Purchase Order for Multiple APAS Instruments
March 15, 2022
LBT Investor Call to discuss CCS Acquisition
January 10, 2022
LBT Completes CCS Acquisition
January 3, 2022
LBT to Obtain Full Ownership of CCS Joint Venture
December 28, 2021
Market Update - Sales Pipeline and Evaluations
December 7, 2021
US FDA 510(k) Clearance for MRSA Analysis Module
October 28, 2021
CCS Appoints Thermo Fisher as Exclusive US APAS Distributor
September 26, 2021
Appendix 4E and Annual Financial Statements
August 26, 2021
APAS Independence Sales to Health Services Laboratory, UK
May 17, 2021
Appendix 4C - quarterly
April 28, 2021
Market Update - Board Renewal Process
January 31, 2021
$0.75m Funding Awarded for APAS-AMR Analysis Module
September 2, 2020
Oneservice Appointed Managed Service Provider for APAS
July 13, 2020
Proposed issue of Securities - LBT
July 8, 2020
$8M PRIVATE PLACEMENT & LAUNCH OF SPP
July 8, 2020
Trading Halt
July 7, 2020
LBT TEAMS WITH GLOBAL CLINICAL DIAGNOSTICS COMPANY
July 6, 2020